BLAINJECTIONINJECTABLE
Approved
Jul 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
22
Mechanism of Action
PCSK9 Inhibitors
Pharmacologic Class:
PCSK9 Inhibitor
Clinical Trials (5)
Alirocumab in Patients with Sepsis
Started Jan 2023
50 enrolled
Sepsis
Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector
Started Nov 2021
163 enrolled
Primary Hypercholesterolaemia and Mixed DyslipidaemiaAtherosclerotic Cardiovascular Disease
Early Alirocumab to Reduce LDL-C in Myocardial Infarction
Started Jan 2020
0Myocardial InfarctionDyslipidemias
Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 Diabetes
Started Feb 2019
22 enrolled
Type2 Diabetes
Long Term Safety Study of PRALUENT
Started Sep 2018
1,389 enrolled
Heterozygous Familial HypercholesterolemiaNon-familial Hypercholesterolemia